Successful Treatment Of Lung Adenocarcinoma With Gefitinib Based On Egfr Gene Amplification
JOURNAL OF THORACIC DISEASE(2018)
Abstract
In the past, the optimal first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with wild-type for epidermal growth factor receptor (wt-EGFR) has been platinum-based chemotherapy doublets (1,2). More recently, clinicians have adopted immunotherapy with check-point inhibitors alone, in PD-L1 strong positive, or combined with chemotherapy independently to PD-L1 expression (3).
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined